Clinical Trials Browser

OTHER × Lapatinib × 1 year × Clear all

NCT01589861 2026-04-21

PIKHER2

Phase 1/2 Terminated

Breast Neoplasms

NCT01612351 2026-03-17

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Phase 2 Completed

40 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT07416409 2026-02-18

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

Breast Neoplasms, Neoplasms

NCT02158507 2026-01-22

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Phase NA Completed

20 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT01382706 2025-10-09

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Phase 2 Terminated

15 enrolled 10 charts

Urinary Bladder Neoplasms

NCT02029001 2025-08-07

MOST plus

Phase 2 Recruiting

Neoplasm Metastasis

NCT02230553 2025-07-08

M14LTK

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT04608409 2025-06-29

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Phase 1 Completed

16 enrolled 14 charts

Ovarian Neoplasms

NCT01273610 2025-06-10

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

Phase 2 Active not recruiting

40 enrolled 15 charts

Breast Neoplasms, Patient Compliance